Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
复制标题
基于渗透泵的药物输送用于中枢神经系统体内髓鞘再生研究
DOI：
10.3791/63343
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Jianqin Niu
中科院分区：
文献类型：
--
作者：
Xiaorui Wang;Yixun Su;Xuelian Hu;Jianqin Niu
不仅在多发性硬化症（MS）中确定了脱髓鞘，而且还发现了其他中枢神经系统疾病，例如阿尔茨海默氏病和自闭症。正如有证据表明，再髓力可以有效缓解疾病症状，因此越来越重视药物开发以促进髓磷脂再生过程。因此，需要一种可选择和可靠的药物输送技术来测试这些药物在体内的效率和特异性。该协议将渗透泵植入物引入了溶血石诱导的脱髓鞘小鼠模型中的一种新药物输送方法。渗透泵是一种可绕过血脑屏障（BBB）并直接将药物稳定地传递到小鼠脑的特定区域的小型植入式装置。它还可以有效地改善具有短寿命的肽和蛋白质等药物的生物利用度。因此，这种方法对中枢神经系统髓鞘再生研究具有很大价值。
Demyelination has been identified in not only multiple sclerosis (MS), but also other central nervous system diseases such as Alzheimer's disease and autism. As evidence suggests that remyelination can effectively ameliorate the disease symptoms, there is an increasing focus on drug development to promote the myelin regeneration process. Thus, a region-selectable and result-reliable drug delivery technique is required to test the efficiency and specificity of these drugs in vivo. This protocol introduces the osmotic pump implant as a new drug delivery approach in the lysolecithin-induced demyelination mouse model. The osmotic pump is a small implantable device that can bypass the blood-brain barrier (BBB) and deliver drugs steadily and directly to specific areas of the mouse brain. It can also effectively improve the bioavailability of drugs such as peptides and proteins with a short half-life. Therefore, this method is of great value to the field of central nervous system myelin regeneration research.